Biogen shares at a four month high, analysts still watch BIIB

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 15:08.

Biogen (US09062X1037) finished Friday at $216.03 on Nasdaq, a four-month high and 6.97 percent above the prior close. MarketBeat lists the move after the 26 June closing print and places the shares close to the top of their 52-week range MarketBeat quote page.

What the price action shows

The Nasdaq listing matters here. BIIB also trades near the upper end of its 50-day band, with MarketBeat showing a 50-day range from $176.02 to $216.03.

That leaves the stock with a clear reference point for the new week. The latest print also stands well above the extended-hours level of $215.50 shown by MarketBeat on 26 June.

Analysts and peers

MarketBeat labels Biogen as one of its most-upgraded Nasdaq names, which gives the shares a visible analyst and sentiment anchor on the US market. The page also identifies Biogen as a biotechnology company in the medical sector Finanzen100 profile with ISIN.

For peer context, Biogen sits in the same US biotech lane as companies such as Moderna and BioNTech. That comparison matters because the group trades on trial updates, pipeline data, and regulatory news rather than on classic industrial metrics.

Biogen’s core business

Biogen’s business centers on neuroscience and rare disease therapies, with products and programs spanning multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease. The company also markets treatments under names such as Tecfidera, Spinraza, and Leqembi.

Biogen on Nasdaq

The Biogen shares (US09062X1037) trade on Nasdaq at $216.03, with the closing print dated 2026-06-26, 16:00 Eastern.

Disclaimer: This article is for information only and does not constitute investment advice.